Lemaitre Vascular (LMAT) Non-Current Debt (2020 - 2021)
Lemaitre Vascular's (LMAT) quarterly Non-Current Debt came in at $22.4 million in Q2 2021, down 39.31% year-over-year from $37.0 million in Q2 2020, and down 21.19% quarter-over-quarter from $28.5 million in Q1 2021.
Powered by 
Analysis
Lemaitre Vascular (LMAT) Non-Current Debt (2020 - 2021) Analysis & Trends
Lemaitre Vascular (LMAT) has reported Non-Current Debt for 2 consecutive years, with $22.4 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Non-Current Debt fell 39.31% year-over-year to $22.4 million in Q2 2021; TTM through Jun 2021 was $22.4 million, a 39.31% decrease from a year earlier, with the FY2020 full-year figure at $35.5 million, changed N/A from the prior year.
- Non-Current Debt was $22.4 million for Q2 2021 at Lemaitre Vascular, down from $28.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $37.0 million in Q2 2020 and troughed at $22.4 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 29.60 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 25.62 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 14.19 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 10.92 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 598.70 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -1.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | - |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 1.65 Bn |
| 10 | Lemaitre Vascular | 1.80 Bn | 1.43 Bn | 50.76 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 22.45 Mn |
| Mar 31, 2021 | 28.49 Mn |
| Dec 31, 2020 | 35.53 Mn |
| Sep 30, 2020 | 36.23 Mn |
| Jun 30, 2020 | 36.99 Mn |